The levels of antibody against SARS-CoV-2 S protein and ACE2 binding inhibition responses after one dose BNT162b2 (Pfizer-BionNTech) mRNA vaccination of individuals who had been previously infected with SARS-CoV-2 were similar to those of two dose vaccinated individuals without prior infection. This suggests that single dose vaccination is sufficient for individuals with prior SARS-CoV-2 infection.
No comments:
Post a Comment